Scarica l'app Stockscreener
2.0899
4.40%
0.0899
Precedente Chiudi:
$2.00
Aprire:
$2.01
Volume 24 ore:
107.32K
Relative Volume:
0.19
Capitalizzazione di mercato:
$16.90M
Reddito:
$1.73M
Utile/perdita netta:
$-23.50M
Rapporto P/E:
-0.4784
EPS:
-4.3682
Flusso di cassa netto:
$-19.37M
1 W Prestazione:
+1.85%
1M Prestazione:
-41.61%
6M Prestazione:
-70.17%
1 anno Prestazione:
-75.72%
Intervallo 1D:
$1.906
$2.13
Intervallo di 1 settimana:
$1.906
$2.37
Portata 52W:
$1.906
$18.80
VolitionRX Ltd Stock (VNRX) Company Profile
Nome
VolitionRX Ltd
Settore
Industria
Telefono
646 650 1351
Indirizzo
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
2.09 | 16.18M | 1.73M | -23.50M | -19.37M | -4.3682 |
TMO
Thermo Fisher Scientific Inc
|
440.99 | 162.90B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
164.09 | 114.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
543.38 | 41.71B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
333.63 | 32.32B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.51 | 31.57B | 7.07B | 1.29B | 993.00M | 4.5355 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Iniziato | Maxim Group | Buy |
| 2018-05-14 | Reiterato | The Benchmark Company | Buy |
| 2016-09-07 | Reiterato | Rodman & Renshaw | Buy |
| 2016-02-01 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
VolitionRX Ltd Borsa (VNRX) Ultime notizie
VolitionRx Limited (AMEX:VNRX) Q1 2026 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth - GuruFocus
VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk - TipRanks
VolitionRx director Mickie Henshall to step down, board size to be reduced - Investing.com Australia
VolitionRx director Mickie Henshall to step down, board size to be reduced By Investing.com - Investing.com South Africa
Mickie Henshall to Leave Volition Board; Company to Reduce Board Size - TradingView
VolitionRx (VNRX) director exits at 2026 meeting as board shrinks to seven - Stock Titan
Lagoda holds 17.07M VolitionRX shares after amendment (VNRX) - Stock Titan
Earnings call transcript: VolitionRx Q1 2026 sees revenue surge, EPS miss - Investing.com
Full Transcript: VolitionRX Q1 2026 Earnings Call - Benzinga
Q1 2026 VolitionRX Ltd Earnings Call Transcript - GuruFocus
VolitionRx : Short Corporate Deck, May 2026 - marketscreener.com
VNRX Stock Price, Quote & Chart | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
Is VolitionRX (VNRX) a Value Trap After Q1 2026? EPS Not Disclos - GuruFocus
VolitionRX: Q1 Earnings Snapshot - marketscreener.com
VolitionRx Ltd stock (US92852X1037): Q1 2026 update and epigenetics business profile - AD HOC NEWS
Rising revenue but cash risk at VolitionRx (NYSE: VNRX) in Q1 2026 - Stock Titan
VolitionRx (NYSE: VNRX) lifts Q1 2026 revenue and secures new funding - Stock Titan
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update - Yahoo Finance
VolitionRx (VNRX) seeks approval to cut authorized shares and adopt 2026 equity plan - Stock Titan
VNRX Technical Analysis | Trend, Signals & Chart Patterns | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
TradingKey - TradingKey
Earnings Preview: VolitionRX to Report Financial Results Pre-market on May 15 - Moomoo
Press Release: VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update - Moomoo
MSN Money - MSN
VolitionRx (VNRX) Advances Feline Cancer Detection Research with New Submission - GuruFocus
BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports High Accuracy In Feline Cancer Blood Test Study - StreetInsider
A blood test for cat lymphoma showed 86% detection at 97% specificity - Stock Titan
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats - Financial Times
User - The Chronicle-Journal
VolitionRx Limited 2025 Annual Report: Executive Compensation, Director Ownership, and Corporate Governance Insights - Minichart
VolitionRX Limited (VNRX) Investment Case | Q4 2025: Earnings UnderperformEV/EBITDA - Newser
VolitionRX | 10-K/A: Annual report (Amendment) - Moomoo
CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX) - Stock Titan
VolitionRx (VNRX) Achieves Breakthrough in Sepsis Detection with New Test - GuruFocus
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing - Barchart.com
Sepsis finger-prick test works in hospital study, opening home-use path - Stock Titan
VolitionRx Limited Announces Amendment to Certificate of Incorporation in April 2026 8-K Filing - Minichart
VolitionRx (NYSE: VNRX) implements 1-for-20 reverse stock split - Stock Titan
DISCLOSED: 5 Stocks Congress Just Bought (PC6HZG2Kcg) - Fathom Journal
Is VolitionRX Limited (VNRX) stock forming a clear pattern | Q4 2025: EPS Misses EstimatesFCF Yield - newser.com
VolitionRX | 8-K: Current report - Moomoo
VNRX Should I Buy - Intellectia AI
VolitionRx receives NYSE American compliance plan approval By Investing.com - Investing.com Australia
VolitionRx receives NYSE American compliance plan approval - Investing.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing - Stock Titan
VolitionRx shares stay on NYSE as exchange accepts compliance plan - Stock Titan
D Boral Capital downgrades VolitionRx (VNRX) - MSN
VolitionRx launches online shop for recombinant nucleosomes By Investing.com - Investing.com Australia
VNRX Downgraded by D. Boral Capital -- Rating Changed to Hold - GuruFocus
VolitionRX Ltd Azioni (VNRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):